@Rossi70 I'm not wrong...i'm just saying what Fuji have said relatively recently and they know the approval process in Japan better than you or I do, in part because they (with Cynata) are actually having meetings with the regulator in relation to this.
Note also, gvhd is a relatively short trial.
Yes re FDA being significantly influenced by successful commercialisation abroad. My knowledge on this point is quite general but perhaps someone on here can identify specific examples.
Fuji WARF and the extension, page-25
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CYP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.5¢ |
Change
0.010(5.13%) |
Mkt cap ! $37.01M | |||
| Open | High | Low | Value | Volume |
| 20.5¢ | 20.5¢ | 20.5¢ | $480 | 2.343K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 15128 | 19.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.5¢ | 43657 | 1 |
View Market Depth
| Last trade - 15.39pm 02/09/2024 (20 minute delay) ? |
| CYP (ASX) Chart |